Algernon Pharmaceuticals targets first human study for its DMT stroke program in 4Q 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (FRA:AGW) (OTCQB:AGNPF) has announced that all of the required permits and licenses for the manufacture of its AP-188 (N, N-Dimethyltryptamine or DMT) have been received.
As a result, the company said it is targeting its Phase 1 human study to be conducted at Hammersmith Medicines Research in the UK in the fourth quarter of 2021.
Algernon said it awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of DMT to Canada-based Dalton Pharma Services.
READ: Algernon Pharmaceuticals expands Ifenprodil research to pancreatic cancer in new clinical study
The Vancouver-based company said the planned Phase 1 study will investigate the safety, tolerability, and pharmacokinetics of intravenous DMT infusion in healthy volunteers with no prior history of psychedelic exposure. Specifically, the trial will aim to identify a sub-hallucinogenic dosing regimen to support planned clinical studies in stroke patients.
Meanwhile, Algernon also announced that its first preclinical study with research-grade DMT is now underway with Charles River Laboratories. The site in Kuopio, Finland is recognized as a world leader for preclinical stroke studies.
The company said the in vitro experiments will provide information on the duration and dose of infusion needed to achieve maximal cortical neurite outgrowth as well as the underlying mechanism of the drug’s action. These experiments will also inform the design of confirmatory animal stroke studies also planned at Charles River and scheduled for later this year.
“While there are many companies that are working in or attempting to enter the psychedelic drug space, many are a considerable distance from human studies,” said Algernon CEO Christopher Moreau in a statement. “We announced that we plan to be the first company globally to investigate DMT for stroke and that is a goal that we are getting closer to achieving.”
Algernon has filed provisional patents for new forms of DMT, in addition to formulation, dosage, and method of use claims for ischemic stroke. The company has also filed claims for combination therapy of DMT and Constraint-Induced Movement Therapy.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/952595/algernon-pharmaceuticals-targets-first-human-study-for-its-dmt-stroke-program-in-4q-2021-952595.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
